<?xml version='1.0' encoding='utf-8'?>
<document id="25470032"><sentence text="An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers."><entity charOffset="48-60" id="DDI-PubMed.25470032.s1.e0" text="ketoconazole" /><entity charOffset="84-93" id="DDI-PubMed.25470032.s1.e1" text="GSK239512" /><pair ddi="false" e1="DDI-PubMed.25470032.s1.e0" e2="DDI-PubMed.25470032.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25470032.s1.e0" e2="DDI-PubMed.25470032.s1.e1" /></sentence><sentence text="This open label drug-drug interaction (DDI) study investigated the effect of a strong CYP3A inhibitor ketoconazole on the PK and safety profile of GSK239512"><entity charOffset="102-114" id="DDI-PubMed.25470032.s2.e0" text="ketoconazole" /><entity charOffset="147-156" id="DDI-PubMed.25470032.s2.e1" text="GSK239512" /><pair ddi="false" e1="DDI-PubMed.25470032.s2.e0" e2="DDI-PubMed.25470032.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25470032.s2.e0" e2="DDI-PubMed.25470032.s2.e1" /></sentence><sentence text=" To mitigate the tolerability concerns of high GSK239512 exposures resulting from CYP3A inhibition, a 2-cohort adaptive design was used to facilitate a stepwise selection of dose levels and subject numbers" /><sentence text=" In Cohort 1, 6 subjects received a single dose of 20 μg GSK239512 alone and then 10 μg GSK239512 in combination with repeated once daily doses of 400 mg ketoconazole"><entity charOffset="154-166" id="DDI-PubMed.25470032.s4.e0" text="ketoconazole" /></sentence><sentence text=" The results from Cohort 1 demonstrated an approximately 1" /><sentence text="5-fold increase in GSK239512 exposure with a good tolerability profile" /><sentence text=" This led to the adoption of a 3-session option in Cohort 2, in which 16 subjects received sequential single doses of 20 μg GSK239512 alone, 40 μg GSK239512 alone, and a single dose of 40 μg GSK239512 in combination with repeated once daily doses of 400 mg ketoconazole"><entity charOffset="257-269" id="DDI-PubMed.25470032.s7.e0" text="ketoconazole" /></sentence><sentence text=" The 2-cohort adaptive design proved effective in mitigating any potentially significant DDI risk to healthy subjects" /><sentence text=" Final results showed a 1" /><sentence text="3-fold increase in GSK239512 exposure with ketoconazole, suggesting that in vivo metabolism of GSK239512 by CYP3A is unlikely to be the primary route of GSK239512 elimination"><entity charOffset="43-55" id="DDI-PubMed.25470032.s10.e0" text="ketoconazole" /></sentence><sentence text=" " /></document>